Category: Prohost Letters
Highlighting Gene Editing Firms
The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is Currently the Best Way - Stopping aberrant genes from causing diseases has taken time to move from wishful thinking to reality. Through trial and...
Read More
March 12, 2018
0
In the Limelight
The Week in Review #18 The Market - The stock market recuperated most of its losses while analysts preferred to abstain from forecasting and remain bystanders during the market volatility. Although the causes of volatility have yet to be delineated,...
Read More
February 19, 2018
0
Positive News
The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage small firm called Proteostasis Therapeutics (PTI) announced positive preliminary results from ongoing Phase 1 cystic fibrosis studies. The trial involved the firm’s proprietary combination...
Read More
October 22, 2018
0
The Prohost Portfolio: Updating the Stock Targets
Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we believe have solid scientific fundamentals and dedicated managements. All the firms in the portfolio, except a few, have proprietary technologies, which enable the firms’...
Read More
March 15, 2018
0
Observing Queer Stories
Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-ban for extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for a...
Read More
March 2, 2018
0
We call it the bad market
The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of the interest rate does not and should not mean a demise of the companies trading on the NASDAQ and other stock exchanges. The biotech...
Read More
October 30, 2018
0
Prohost Letter #406
Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX Vertex (VRTX) : Great news about 2016 revenues & earnings Growth and pipeline. FROM YESTERDAY : Tremendous Revenues Growth. Cystic fibrosis (CF) revenues grew...
Read More
March 13, 2017
0
Prohost Letter #405
Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic biology firm called Synthetic Genomics turns public. We reiterate that firms specialized in synthetic biology are numerous private and publicly traded. Some are promising,...
Read More
March 10, 2017
0
Improving on immunotherapy and preventing one of its serious side effects
The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. Removal of glutamine leads to a substantial reduction in cell growth or induces cell death in certain types of cancer cells , indicating that...
Read More
November 13, 2018
0
An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio
The Week in Review #22 What Went Right or Wrong in the Biotech Sector During the Departing Week? - A lot happened in the biotech sector during the week, which departed at midnight. Topping the list of the week’s events...
Read More
May 7, 2018
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)